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The term epilepsy is a collective term that includes disorders of the brain function
characterized by the periodic and unpredictable occurrence of seizures. Epilepsies are
common and frequently devastating and affect around 1–2 % of the world population (1).
Current drug therapy for epilepsy suffers from a number of disadvantages, includ-
ing the fact that the convulsions of approximately 25 % of epileptics are inadequately
controlled by medication (2). In recent years, the field of antiepileptic drug development
has become quite dynamic, affording many promising research opportunities.
In our previous study (3–5), we designed aryl-substituted semicarbazones with ben-
zothiazole moiety, in which we made some modifications in the structure of semicar-
bazones. The lipophilic aryl ring was replaced with a versatile heterocyclic molecule ben-
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zothiazole, which possesses significant anticonvulsant properties. On the other hand,
thiadiazole moiety was also found to possess significant anticonvulsant activity (6, 7). In
continuation of our previous research on benzothiazoles, we report here the synthesis
and anticonvulsant activity of several N-(5-chloro-6-substituted-benzothiazol-2-yl)-N'-(sub-
stituted phenyl)-[1,3,4]thiadiazole-2,5-diamines. Incorporation of 1,3,4-thiadiazole moi-
ety into the second position of the benzothiazole ring may result in compounds having
better anticonvulsant activity. The neurotoxicity as well as liver toxicity of the compounds
has also been evaluated.
EXPERIMENTAL
The chemicals and solvents used for the experimental work were commercially pro-
cured from E. Merck, CDH, S. D. Fine Chem. and Qualigens, all from India. The silica
gel G used for analytical chromatography (TLC) was obtained from E. Merck, India.
Melting points were determined in an open glass capillary using a Kjeldahl flask con-
taining paraffin and are uncorrected. The proton magnetic resonance spectra (1H NMR)
were recorded on a Bruker 300 MHz instrument (Bruker, Germany) in DMSO-d6 using
tetramethylsilane [(CH3)4Si] as internal standard. Chemical shifts (d) are expressed in ppm.
The infrared spectra of compounds (in cm–1) were recorded in KBr on a Bio-Rad FTIR
(Browser Morner, USA) spectrometer. Elemental analyses were performed on a 240c an-
alyzer (Perkin Elmer, USA).
Syntheses
5-Chloro-6-substituted-benzothiazol-2-ylamines (1a,b). – A mixture of substituted ani-
line (0.01 mol) and potassium thiocyanate (0.01 mol) in glacial acetic acid was cooled
and stirred. To this solution, bromine (0.01 mol) was added dropwise at such a rate to
keep the reaction temperature below 10 °C throughout the addition. Stirring was contin-
ued for additional 3 h and the separated hydrochloride salt was filtered, washed with
acetic acid and dried. It was dissolved in hot water and neutralized with aqueous am-
monia solution (25 %). The precipitate obtained was filtered, washed with water, dried
and recrystallized to afford the 6-substituted-1,3-benzothiazol-2-amine (1a,b). Yield: 64
%; m.p. 248 °C; IR (KBr) cm–1: 3239 (NH2), 3016 (CH-Ar), 1562 (C=N), 804 (C-Cl); 1H
NMR (DMSO-d6) d ppm: 7.89–8.16 (m, 2H, ArH), 9.76 (s, 2H, NH2, D2O exchangeable).
(5-Chloro-6-substituted-benzothiazol-2-yl)-ureas (2a,b). – To a solution of sodium cya-
nate (0.5 g) in minimum quantity of water, glacial acetic acid (5 mL) was added. This so-
lution was heated with the respective 2-amino-6-substituted benzothiazoles (1.7 g, 0.01
mol) in alcohol till the mixture contents became turbid and the volume was half of the
original volume. The contents were added to ice cool water. The solid obtained was fil-
tered off and dried. Yield: 73 %; m.p. 262 °C; IR (KBr) cm–1: 3218 (NH), 3165 (NH2), 2937
(CH-Ar), 1678 (C=O), 1545 (C=N), 816 (C-Cl); 1H NMR (DMSO-d6) d ppm: 7.82–8.20 (m,
2H, ArH), 9.14 (s, 2H, NH2, D2O exchangeable), 9.86 (s, 1H, NH, D2O exchangeable).
N-(5-Chloro-6-substituted-benzothiazol-2-yl)hydrazine carboxamides (3a,b). – To a solution
of substituted benzothiazole urea (2a,b, 0.01 mol) in ethanol, hydrazine hydrate (0.01
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mol) and NaOH (0.04 g) were added. The resulting mixture was refluxed for 16 h. It was
then concentrated, cooled and poured over crushed ice to get the precipitate, which was
filtered, washed with water and recrystallized from ethanol to get hydrazine carboxami-
des. Yield: 71 %; m. p. 224 °C; IR (KBr) cm–1: 3265, 3218 (NH), 3112 (NH2), 3017 (CH-Ar),
1683 (C=O), 1513 (C=N), 845 (C-Cl); 1H NMR (DMSO-d6) d ppm: 7.74–8.12 (m, 2H, ArH),
8.98 (s, 2H, NH2, D2O exchangeable), 9.41 (s, 1H, NH, D2O exchangeable), 9.86 (s, 1H,
NH, D2O exchangeable).
N-(5-Chloro-6-substituted-benzothiazol-2-yl)-2-[(4-substituted phenyl)carbamothioyl] hydra-
zinecarboxamides (4a-t). – A solution of carboxamides in glacial acetic acid (5 mL) and etha-
nol (10 mL) was heated to boiling and refluxed with aromatic ketones (1 g, 0.122 mol)
for 5 h. Refluxed solution was cooled to room temperature and kept overnight. The solid
was collected out, washed with methanol, dried and recrystallized from ethanol to get
the target compound. Yield: 58 %; m.p. 269 °C; IR (KBr) cm–1: 3285, 3245, 3212, 3176
(NH), 3006 (CH-Ar), 1673 (C=O), 1534 (C=N), 1055 (C=S), 832 (C-Cl); 1H NMR (DMSO-
-d6) d ppm: 6.76–8.32 (m, 7H, ArH), 8.52 (s, 1H, NH, D2O exchangeable), 8.75 (s, 1H,
NH, D2O exchangeable), 9.18 (s, 1H, NH, D2O exchangeable), 9.49 (s, 1H, NH, D2O ex-
changeable).
N-(5-Chloro-6-substituted-benzothiazol-2-yl)-N’-(substituted phenyl)-[1,3,4]thiadiazole-
-2,5-diamines (5a-t). – To cold concentrated sulphuric acid (25 mL), compounds (4a-t, 0.01
mol) were added gradually under constant stirring. After the addition was completed,
the solution was kept at room temperature for 2 h and poured onto crushed ice. The
solid thus separated was washed with water and treated with a dilute solution of so-
dium bicarbonate. The product obtained was washed with water, dried and recrystalli-
zed from ethanol to afford the titled compounds (5a-t).
Pharmacology
Anticonvulsant activity. – Anticonvulsant evaluation was undertaken using a repor-
ted procedure (8, 9). Albino mice (Swiss, 25–30 g) were used in groups of six each as ex-
perimental animals. The test compounds and standard drug were suspended in Tween
80 (1 %) or in a 0.5 % methyl cellulose-water mixture and administered intraperitoneally.
The animals were maintained on an adequate diet and allowed free access to food and
water except during the short time they were removed from cages for testing. The ani-
mals were maintained at room temperature (25 ± 2 °C). All the experimental protocols
were carried out with the permission of the Institutional Animal Ethics Committee (IAEC).
Animals were obtained from the Central Animal House Facility, Jamia Hamdard Uni-
versity, New Delhi, India.
Maximal electroshock seizure test (MES). – Maximal electroshock seizure was elicited
with a 60 cycle alternating current of 50 mA intensity delivered for 0.25 s via ear clip
electrodes. Maximal seizure typically consists of a short period of tonic extension of
the hind limbs and a final clonic episode. Abolition of the hind limb tonic extensor
component of the seizure is defined as protection and the results are expressed as %
protection.
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Neurotoxicity (NT). – The rotarod test was used to evaluate neurotoxicity (10). The
animal was placed on a 3.2-cm diameter knurled rod rotating at 6 rpm. Normal mice can
remain indefinitely on a rod rotating at this speed. Neurological toxicity is defined as the
failure of the animal to remain on the rod for 1 min. Results are expressed as the number
of animals exhibiting toxicity/number of animals tested.
Assessment of liver function. – Biochemical parameters such as serum glutamate oxa-
loacetate transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT) were
estimated by the Reitman and Frankel method (11) and alkaline phosphatase was mea-
sured using the King and Armstrong method (12). Total protein and total albumin were
also measured according to the biuret method (13).
Statistical analyses. – All the statistical analyses were performed using the SigmaStat
version 4.0 software and ANOVA followed by Dunnett’s multiple comparison test.
RESULTS AND DISCUSSION
N-(5-chloro-6-substituted-benzothiazol-2-yl)-N'-(substituted phenyl)-[1,3,4]thiadia-
zole-2,5-diamines (5a-t) were synthesized by the sequence described in Scheme 1. Initial
compounds, 5-chloro-6-substituted-1,3-benzothiazol-2-amines (1a,b), were synthesized
by treating arylamines with potassium thiocyanate. The 5-chloro-6-substituted-benzo-
thiazol-2-yl-ureas (2a,b) were prepared by treating appropriate benzothiazole with so-
dium cyanate in the presence of glacial acetic acid. Further N-(5-chloro-6-substituted-1,3-
-benzothiazol-2-yl) hydrazine carboxamides (3a, b) were obtained by refluxing them with
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hydrazine hydrate to yield carboxamides. The final compounds (5a-t) were obtained by
refluxing carboxamides with different substituted phenyl isothiocyanates in ethanol and
then cyclizing them in the presence of cold concentrated sulphuric acid. Physicochemi-
cal parameters of the synthesized compounds are presented in Table I.
The structures and purity of the final compounds were confirmed on the basis of
spectral and elemental analyses and the data were within ± 0.4 % of theoretical values
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(Table II). The FTIR spectra showed bands at 3370–3153 cm–1 for the NH and 1674–1633
and 720–689 cm–1 for C=O and C-S-C, respectively. The 1H NMR spectra showed two
singlets at d 8.85–9.30 and 11.14–11.78 ppm for the two NH protons.
Pharmacology
1-(5,6-Disubstituted-1,3-benzothiazol-2-yl)-3-[5-(4-substituted phenyl)-1,3,4-thiadia-
zol-2-yl urea derivatives (5a-t) obtained from the reactional sequence were injected in-
traperitoneally into mice and evaluated by the maximal electroshock (MES), neurotoxi-
city screen using rotarod at the dose of 30 mg kg–1 body mass and observations were
carried out at two different time intervals of 0.5 and 4 h. The data are presented in Table
III. Phenytoin was used as the standard for the comparison at the dose level of 30 mg
kg–1. All the compounds showed anti-MES activity indicative of their ability to prevent
seizure spread. The compounds that showed 100 % protection against the MES model at
30 mg kg–1 body mass were 5b, 5c both after 0.5 and 4 h. Compounds 5k, 5o, 5e and 5f
showed 83 % protection at both time intervals except for compound 5o, which showed
66 % protection after 4 h, indicating a rapid onset and shorter duration of action. Com-
pounds 5d, 5j, 5l, 5r and 5t had 66 % protection, whereas compounds 5a, 5g, 5h, 5i, 5m,
5n, 5p, 5q and 5s were 50 % protective in the anti-MES screen. In the neurotoxicity screen,
compounds with 83–100 % protection were selected and checked for neurotoxicity at the
dose of 30 mg kg–1. None of the compounds displayed neurotoxicity, since they success-
fully passed the rotarod test without any sign of motor impairment (Table III). Bioeva-
luation led to correlation of the anticonvulsant screening with the basic structure of the
compounds. In general, the disubstituted benzothiazole ring with 5,6-Cl substituents had
higher potency than the 5-Cl and 6-F substitution. Disubstitution with Cl at the 5,6 posi-
tion of the benzothiazole ring and 4-Br, 3-Cl substituents at the distant phenyl ring re-
sulted in highly potent compounds, whereas replacement with 5-Cl, 6-F at the benzo-
thiazole ring and H, 3-Cl, 3-CH3, 2-OCH3, 3-OCH3, 4-CH3, 4-Cl, 4-F substituents at the
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a Solvent of crystallization: methanol.
b Melting point of the compounds at decomposition.
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Table II. Spectral characterization of synthesized compounds
Compd.
No.
FT-IR (KBr, cm–1) 1H NMR (DMSO-d6, d ppm)
13C NMR (CDCl3, TMS,
d ppm)
5a
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distant phenyl ring led to a 50 % decrease in potency. Disubstitution with 5,6-Cl and 5-Cl,
6-F at the benzothiazole ring and 4-F, 3-CH3 at the distant phenyl ring resulted in com-
pounds with highly significant activity. Compounds with disubstitution such as 5,6-Cl
and 5-F, 6-Cl and 4-Br, 4-Cl or 4-OCH3, 2-OCH3 at the distant phenyl ring had significant
activity.
Enzyme estimation and histopathological studies of the selected compounds 5b and
5c showing 100 % protection were also performed to check the magnitude of liver toxi-
city and the data are presented in Table IV. The concentrations of alkaline phosphatase,
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Table III. Anticonvulsant and neurotoxicity screening of compounds 5a-t
Compd.
No.
Intraperitoneal injection in micea
MES screen protection (%) Neurotoxicity screen
Time (h)
0.5 4 0.5 4
Control – – – –
5a 50 50 NT NT
5b 100 100 – –
5c 100 100 – –
5d 66 66 NT NT
5e 83 83 – –
5f 83 83 – –
5g 50 50 NT NT
5h 50 50 NT NT
5i 50 50 NT NT
5j 66 66 NT NT
5k 83 83 – –
5l 66 66 NT NT
5m 50 50 NT NT
5n 50 50 NT NT
5o 83 83 – –
5p 50 50 NT NT
5q 50 50 NT NT
5r 66 66 NT NT
5s 50 50 NT NT
5t 66 66 NT NT
Phenytoina 100 100 – –
Number of animals tested (n = 6).
a Dose of 30 mg kg–1 was administered i.p. The test compounds and standard drug were suspended in 1 %
Tween 80 or in 0.5 % methylcellulose-water mixture. The animals were examined 0.5 and 4 h after administration.
The (–) indicates the absence of activity and NT denotes not tested.
SGOT, SGPT and total protein were determined and the values are represented as mean
± SEM. Compound 5b showed a significant change in the SGOT and total protein level
compared to the control (p < 0.05), whereas compound 5c was found to increase signifi-
cantly the concentration of all the liver enzymes estimated as well as the total protein
level compared to the control (p < 0.01).
CONCLUSIONS
Thiadiazole incorporated benzothiazole derivatives can be regarded as a new struc-
tural class of anticonvulsant agents. Some of the compounds displayed encouraging acti-
vities in the MES test with less neurotoxicity and minimal effect on the liver. These com-
pounds have promising prospects of future applications.
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S A  E T A K
Sinteza i preliminarna ispitivanja antikonvulzivnog djelovanja
derivata benzotiazol-2-il tiadiazola
NADEEM SIDDIQUI, ARPANA RANA, SUROOR A. KHAN, S. EHTAISHAMUL HAQUE,
M. FAIZ ARSHAD, SHARIQUE AHMED i WAQUAR AHSAN
U radu je opisano dizajniranje i sinteza razli~itih N-(5-klor-6-supstituiranih benzo-
tiazol-2-il)-N'-(supstituiranih fenil)-[1,3,4]tiadiazol-2,5-diamina (5a-t) polaze}i od odgo-
varaju}ih acetofenona. Strukture spojeva odre|ene su na temelju spektroskopskih poda-
taka i elementarne analize. Ispitano je antikonvulzivno djelovanje svih novosintetiziranih
spojeva i uspore|eno s djelovanjem natrijeve soli fenitoina. Spojevi 5b i 5c pru`aju pot-
punu za{titu od konvulzija uzrokovanih MES-om, a svi spojevi {tite od konvulzija u ras-
ponu od 50 do 100 %.
Klju~ne rije~i: benzotiazol, tiadiazol, antikonvulziv, neurotoksi~nost, hepatotoksi~nost
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